Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
Add more filters










Publication year range
1.
Ophthalmol Retina ; 8(8): 733-743, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38519026

ABSTRACT

PURPOSE: To characterize the incidence of kidney failure associated with intravitreal anti-VEGF exposure; and compare the risk of kidney failure in patients treated with ranibizumab, aflibercept, or bevacizumab. DESIGN: Retrospective cohort study across 12 databases in the Observational Health Data Sciences and Informatics (OHDSI) network. SUBJECTS: Subjects aged ≥ 18 years with ≥ 3 monthly intravitreal anti-VEGF medications for a blinding disease (diabetic retinopathy, diabetic macular edema, exudative age-related macular degeneration, or retinal vein occlusion). METHODS: The standardized incidence proportions and rates of kidney failure while on treatment with anti-VEGF were calculated. For each comparison (e.g., aflibercept versus ranibizumab), patients from each group were matched 1:1 using propensity scores. Cox proportional hazards models were used to estimate the risk of kidney failure while on treatment. A random effects meta-analysis was performed to combine each database's hazard ratio (HR) estimate into a single network-wide estimate. MAIN OUTCOME MEASURES: Incidence of kidney failure while on anti-VEGF treatment, and time from cohort entry to kidney failure. RESULTS: Of the 6.1 million patients with blinding diseases, 37 189 who received ranibizumab, 39 447 aflibercept, and 163 611 bevacizumab were included; the total treatment exposure time was 161 724 person-years. The average standardized incidence proportion of kidney failure was 678 per 100 000 persons (range, 0-2389), and incidence rate 742 per 100 000 person-years (range, 0-2661). The meta-analysis HR of kidney failure comparing aflibercept with ranibizumab was 1.01 (95% confidence interval [CI], 0.70-1.47; P = 0.45), ranibizumab with bevacizumab 0.95 (95% CI, 0.68-1.32; P = 0.62), and aflibercept with bevacizumab 0.95 (95% CI, 0.65-1.39; P = 0.60). CONCLUSIONS: There was no substantially different relative risk of kidney failure between those who received ranibizumab, bevacizumab, or aflibercept. Practicing ophthalmologists and nephrologists should be aware of the risk of kidney failure among patients receiving intravitreal anti-VEGF medications and that there is little empirical evidence to preferentially choose among the specific intravitreal anti-VEGF agents. FINANCIAL DISCLOSURES: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.


Subject(s)
Angiogenesis Inhibitors , Bevacizumab , Intravitreal Injections , Ranibizumab , Receptors, Vascular Endothelial Growth Factor , Recombinant Fusion Proteins , Renal Insufficiency , Vascular Endothelial Growth Factor A , Humans , Receptors, Vascular Endothelial Growth Factor/administration & dosage , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/adverse effects , Ranibizumab/administration & dosage , Ranibizumab/adverse effects , Bevacizumab/administration & dosage , Bevacizumab/adverse effects , Angiogenesis Inhibitors/administration & dosage , Angiogenesis Inhibitors/adverse effects , Retrospective Studies , Male , Female , Renal Insufficiency/epidemiology , Renal Insufficiency/complications , Renal Insufficiency/chemically induced , Incidence , Aged , Middle Aged , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Diabetic Retinopathy/drug therapy , Diabetic Retinopathy/epidemiology , Diabetic Retinopathy/diagnosis , Diabetic Retinopathy/complications , Follow-Up Studies , Risk Factors , Macular Edema/drug therapy , Macular Edema/epidemiology , Macular Edema/diagnosis , Retinal Vein Occlusion/drug therapy , Retinal Vein Occlusion/diagnosis , Retinal Vein Occlusion/complications , Retinal Vein Occlusion/epidemiology , Blindness/epidemiology , Blindness/chemically induced , Blindness/prevention & control , Blindness/diagnosis , Blindness/etiology
3.
Arch. Soc. Esp. Oftalmol ; 98(7): 410-412, jul. 2023. ilus
Article in Spanish | IBECS | ID: ibc-222988

ABSTRACT

Mujer de 57 años sin premorbilidades que acude por pérdida de visión súbita e indolora en el ojo derecho (OD). La agudeza visual mejor corregida fue de contar dedos a 10cm. En el OD se observó un defecto pupilar aferente relativo. El examen de fondo de ojo en el OD fue sugestivo de oclusión central de la arteria retiniana. La evaluación sistémica fue normal. Lo más interesante en este caso es que un edema hemorrágico en la región glabelar derecha fue la base de la sospecha diagnóstica. La paciente reconoció la pérdida de visión a las 24horas de la inyección de ácido hialurónico como tratamiento de rejuvenecimiento facial (AU)


A 57-year-old woman with no premorbidities presented with symptoms of sudden painless vision loss in the right eye (RE). Best-corrected visual acuity in the RE was counting fingers to 10cm. A relative afferent pupillary defect was observed in the RE. Ocular fundus examination of RE was suggestive of central retinal artery occlusion. Systemic evaluation was normal. The most interesting fact in this case is that a hemorrhagic edema in the right glabellar region was the basis for the diagnostic suspicion. The patient recognized the loss of vision 24hours after hyaluronic acid injection as a facial rejuvenation treatment (AU)


Subject(s)
Humans , Female , Middle Aged , Hyaluronic Acid/administration & dosage , Hyaluronic Acid/adverse effects , Viscosupplements/administration & dosage , Viscosupplements/adverse effects , Retinal Artery Occlusion/chemically induced , Blindness/chemically induced , Visual Acuity , Injections
4.
Arch. Soc. Esp. Oftalmol ; 97(9): 521-538, sept. 2022. ilus, tab
Article in Spanish | IBECS | ID: ibc-209107

ABSTRACT

Introducción La pérdida visual relacionada con la inyección periocular de rellenos con fines cosméticos es infrecuente pero muy grave. Como recomendaciones protocolizadas ante la pérdida visual por inyección intravascular inadvertida de ácido hialurónico se encuentran, entre otras, la inyección de hialorunidasa en el espacio retroocular. Es de esperar que, dada la creciente demanda de tratamientos de rellenos estéticos y la gran heterogeneidad de profesionales que pueden administrarlos, el número de casos y complicaciones relacionadas con estos procedimientos se incremente de manera sustancial. Objetivo Evaluar si existe evidencia científica para recomendar la inyección retroocular de hialuronidasa en el tratamiento de pérdidas visuales relacionadas con la inyección periocular de ácido hialurónico cosmético. Material y métodos Hemos realizado una búsqueda de artículos publicados en inglés y español siguiendo la declaración PRISMA sobre el uso de hialuronidasa retrobulbar para revertir la pérdida de visión producida por los rellenos de ácido hialurónico. Los artículos revisados incluyeron los casos clínicos y las investigaciones experimentales. Identificamos a un total de 13 pacientes en esta revisión siguiendo unos criterios de inclusión y exclusión definidos. Finalmente, incluimos 15 artículos en el estudio, 13 de ellos fueron casos/series de casos. Los 2artículos restantes son estudios experimentales en animales con grupo control, en los que, tras provocar una oclusión selectiva de la arteria oftálmica, se administran inyecciones seriadas de hialuronidasa retroocular con control de la función visual. Resultados De los 15 artículos incluidos en el estudio, recogimos los datos de un total de 17 pacientes que, tras inyección de ácido hialurónico facial por motivos estéticos, presentaron una disminución brusca de la visión y en los que se inyectaron dosis variables de hialuronidasa retroocular (AU)


Introduction Blindness after periocular cosmetic filler injection is a rare but devastating complication. Complication management protocols recommend injecting retrobulbar hyaluronidase if visual loss related to accidental intravascular injection of hyaluronic acid occurs. Given the dramatic increase in cosmetic filler injections and the variety of professionals that can deliver them, it is reasonable to assume that the incidence of complications will rise significantly. Objective To evaluate if there is evidence-based efficacy of retrobulbar hyaluronidase injection in visual loss secondary to periocular cosmetic filler injection. Material and methods The authors performed a search of English and Spanish language articles following the PRISMA statement published on the use of retrobulbar hyaluronidase to reverse vision loss precipitated by hyaluronic acid gel fillers. Articles reviewed included case reports/series and experimental investigations. We identified a total of 13 patients in this review following defined inclusion and exclusion criteria. Finally, we included 15 articles in the study, 12 of them were cases / case series. The 2remaining articles are experimental studies in animals with a control group, in which after causing selective occlusion of the ophthalmic artery, serial injections of retroocular hyaluronidase are administered with control of visual function. Results Of the 15 articles included in the study, we studied 17 patients treated with retrobulbar hyaluronidase for hyaluronic acid-induced blindness. Improvement was demonstrated in 3 cases. Animal studies demonstrate variable data are provided regarding the recovery of visual acuity. Conclusions There is no confirmed evidence of retrobulbar hyaluronidase injection effectiveness in treating visual loss due to accidental intravascular injection of hyaluronic acid. More studies are needed to show the efficacy of hyaluronidase as a treatment for blindness caused by hyaluronic acid (AU)


Subject(s)
Humans , Blindness/chemically induced , Blindness/drug therapy , Dermal Fillers/adverse effects , Hyaluronic Acid/adverse effects , Viscosupplements/adverse effects , Hyaluronoglucosaminidase/therapeutic use , Injections, Intraocular/adverse effects
5.
Rev. medica electron ; 43(2): 3257-3269, mar.-abr. 2021. graf
Article in Spanish | LILACS, CUMED | ID: biblio-1251943

ABSTRACT

RESUMEN Se reportó el caso de un paciente con maculopatía en ojo de buey, asociada al uso de cloroquina. El uso de cloroquina en patologías reumatológicas puede provocar daño retinal relacionado con la dosis y el tiempo de evolución del tratamiento. Puede provocar desde afectación visual leve hasta daño irreversible de la visión, lo que depende del tiempo en que se realice el diagnóstico. Se presentó una paciente de 72 años, con diagnóstico de artritis reumatoide desde hace 21 años y tratamiento con cloroquina desde hace 15. Acudió a consulta con disminución de la visión lenta y progresiva bilateral. En el examen oftalmológico de fondo de ojo se diagnosticó maculopatía en ojo de buey. Este diagnóstico se confirmó por estudios de autofluorescencia y por la tomografía de coherencia óptica (AU).


ABSTRACT A case is reported of a patient with maculopathy in bulls' eye associated to the use of chloroquine. The use of chloroquine associated with rheumatologic diseases can cause retinal damage related to the dose and the time of treatment evolution. It can cause from mild visual impairment to irreversible vision damage depending on the time the diagnosis is made. A 72-year-old female patient is presented with a diagnosis of rheumatoid arthritis for 21 years and treatment with chloroquine for 15 years. She assisted the consultation with a slow and progressive bilateral vision decrease; at the ophthalmological examination of the fundus a maculopathy in bull's eye was diagnosed, later confirmed by auto fluorescence and optical coherence tomography studies (AU).


Subject(s)
Humans , Female , Aged , Adonis/drug effects , Macular Degeneration/diagnosis , Blindness/chemically induced , Adonis/toxicity , Macular Degeneration/complications , Macular Degeneration/pathology
6.
Arch. argent. pediatr ; 118(5): e480-e485, oct 2020. ilus, tab
Article in Spanish | LILACS, BINACIS | ID: biblio-1122533

ABSTRACT

Se presentan dos pacientes que desarrollaron deterioro visual debido a una intoxicación por monóxido de carbono. Ellos fueron tratados con oxígeno hiperbárico y recuperaron no solo su visión, sino que, además, mejoraron su signo-sintomatología neurológica. Se cree que la implementación de oxígeno hiperbárico, incluso en un período tardío, será efectiva para revertir las secuelas neurológicas.


We present two patients who developed visual deterioration due to carbon monoxide poisoning. They were treated with hyperbaric oxygen and recovered not only their vision but also they improved neurological signs and symptoms. We believe that implementation of hyperbaric oxygen, even in a late period of time will be effective in reversing neurological sequela


Subject(s)
Humans , Male , Child , Adolescent , Carbon Monoxide Poisoning/complications , Blindness/chemically induced , Hyperbaric Oxygenation , Nervous System Diseases/chemically induced
7.
Arch. Soc. Esp. Oftalmol ; 95(5): 231-235, mayo 2020. ilus
Article in Spanish | IBECS | ID: ibc-198613

ABSTRACT

La intoxicación por ingesta de metanol es una entidad frecuentemente descrita en la literatura, no así la intoxicación vía transdérmica o inhalatoria. Suele cursar con daño multiorgánico variable, entre lo que destaca la afectación visual, neurológica y digestiva, así como las alteraciones metabólicas y electrolíticas que pueden llegar a causar la muerte. El contacto con tolueno por inhalación ocupacional o intencional puede producir también alteraciones neurológicas. En este artículo se expone el caso de una paciente mujer que acude al servicio de urgencias por pérdida visual bilateral secundaria a una intoxicación accidental (inhalatoria-transdérmica) con un disolvente que contenía metanol y tolueno, entre otros compuestos, y que durante el ingreso evoluciona favorablemente tras tratamiento con etanol en perfusión y corticoides


Methanol poisoning is often described in the literature, but not transdermal or inhalational poisoning. It usually involves variable multi-organ damage, among which visual, neurological, and gastrointestinal involvement, as well as the metabolic and electrolyte changes that can lead to death. Contact with toluene by occupational or intentional inhalation may also cause neurological abnormalities. This article describes the case of a female patient who was seen in the Emergency Department due to bilateral visual loss secondary to accidental poisoning (inhalation-transdermal) with a solvent containing methanol and toluene. She had a favourable outcome during admission after treatment with ethanol in perfusion and corticosteroids


Subject(s)
Humans , Female , Middle Aged , Methanol/poisoning , Toluene/poisoning , Blindness/chemically induced , Blindness/diagnostic imaging , Blindness/drug therapy , Tomography, X-Ray Computed , Ophthalmoscopy , Ethanol/therapeutic use , Leucovorin/therapeutic use , Antidotes/therapeutic use , Methylprednisolone/therapeutic use , Glucocorticoids/therapeutic use
8.
Arq. bras. oftalmol ; 82(6): 511-513, Nov.-Dec. 2019. graf
Article in English | LILACS | ID: biblio-1038696

ABSTRACT

ABSTRACT Facial filler injection for soft-tissue augmentation, wrinkle reduction, and rejuvenation has recently become increasingly popular. This procedure is well accepted and widely performed because of its safety and excellent outcomes. However, complications may occur even in the most skilled hands. A 36-year-old female presented with immediate loss of vision in her right eye following the periocular injection of cosmetic hyaluronic acid facial filler into the glabellar region. The visual loss was accompanied by weakness of her left arm. Blindness may complicate cosmetic facial filler injection. The treating physician should have a firm knowledge of the facial vascular anatomy, and the patient should be aware of the potential blinding complications associated with facial filler injection.


RESUMO A injeção de preenchimento facial para o aumento de tecido mole, redução de rugas e rejuvenescimento tornou-se recentemente3 cada vez mais popular. Este procedimento é bem aceito e amplamente realizado devido à sua segurança e excelentes resultados. Porém, complicações podem ocorrer mesmo nas mãos mais habilidosas. Uma mulher de 36 anos apresentou perda da visão no seu olho direito imediatamente após uma injeção periocular de preenchimento facial à base de ácido hialurônico cosmético na região glabelar. A perda visual foi acompanhada de fraqueza no braço esquerdo. A cegueira pode ser uma complicação da injeção de preenchimento facial para fins cosméticos. O médico deve ter um sólido conhecimento da anatomia vascular da face e o paciente deve estar ciente das possíveis complicações associadas à injeção de preenchimento facial.


Subject(s)
Humans , Female , Adult , Blindness/chemically induced , Face , Dermal Fillers/adverse effects , Hyaluronic Acid/adverse effects , Retinal Detachment/chemically induced , Injections, Intradermal/adverse effects , Cosmetic Techniques/adverse effects
10.
Arch. Soc. Esp. Oftalmol ; 81(1): 45-47, ene. 2006. ilus
Article in Es | IBECS | ID: ibc-046719

ABSTRACT

Caso Clínico: Presentamos una rara complicación de la inyección retrobulbar en la cirugía oftalmológica, como es la ceguera y la parálisis de los músculos extraoculares en el ojo contralateral.Nuestro paciente no sufrió secuelas permanentes.Discusión: Se han descrito numerosas complicaciones de la anestesia retrobulbar en el ojo y la órbita. La inyección del agente anestésico en el espacio subdural o subaracnoideo a través de la vaina del nervio óptico (NO) se postula como posible explicación del cuadro. La droga puede alcanzar el quiasma óptico y desde ahí acceder al NO contralateral. Se discuten varios métodos para disminuir la probabilidad de tal afección


Case report: We report a rare complication of retrobulbar anesthesia in ophthalmic surgery- amarurosis and extraocular muscle palsies in the contralateral eye. Our patient did not suffer permanent sequelae from the injection. Discussion: Numerous complications resulting from retrobulbar injections in the eye and orbit have been reported. One possible explanation of this case is the inadvertent penetration of the subdural or subarachnoid space surrounding the optic nerve and the injection of anesthetic into that space. The drug then tracks along the ipsilateral optic nerve to the chiasm and then to the contralateral optic nerve. Several methods of decreasing the probability of such a complication are discussed


Subject(s)
Male , Aged , Humans , Anesthesia/adverse effects , Blindness/chemically induced , Ophthalmoplegia/chemically induced , Subarachnoid Space
11.
Arq. neuropsiquiatr ; 62(3B): 873-874, set. 2004. ilus
Article in English | LILACS | ID: lil-384143

ABSTRACT

A injeção de polimetilmetacrilato (PMMA) é prática difundida na medicina estética como medida rejuvenecedora. No entanto, a injeção facial do PMMA carreia sérios riscos, especialmente se realizada na região glabelar. Descrevemos o caso de uma mulher que imediatamente após injeção glabelar de PMMA apresentou amaurose e oftalmoplegia total, revendo ainda a literatura pertinente.


Subject(s)
Female , Humans , Middle Aged , Blindness/chemically induced , Cosmetic Techniques/adverse effects , Ophthalmoplegia/chemically induced , Polymethyl Methacrylate/adverse effects , Face , Injections, Intradermal , Microspheres , Polymethyl Methacrylate/administration & dosage , Rejuvenation
13.
Bol. Hosp. San Juan de Dios ; 33(6): 430-3, nov.-dic. 1986. ilus
Article in Spanish | LILACS | ID: lil-40180

ABSTRACT

Se presenta un caso clínico de intoxicación aguda por metanol con amaurosis y paraparesia espástica secuelares que no han respondido al tratamiento esteroidal oral ni intratecal. Se detallan los resultados de su estudio electroencefalográfico, electromiográfico y tomográfico axial computado que reveló hipodensidad putaminal bilateral con cisternas silvianas dilatadas. Se revisa en forma general la clínica y el tratamiento de la intoxicación aguda por metanol, señalando suas probables proyecciones a futuro. Se hace una revisión bibliográfica de las secuelas de la intoxicación por metanol, enfatizando las motoras descritas sólo a partir de 1950


Subject(s)
Adult , Humans , Male , Blindness/chemically induced , Dystonia/chemically induced , Methanol/toxicity , Follow-Up Studies , Tomography, X-Ray Computed
14.
Rev. cuba. med ; 25(9): 850-6, sep. 1986. ilus
Article in Spanish | CUMED | ID: cum-2815

ABSTRACT

Se hace una revisión bibliográfica por los autores de la literatura mundial acerca de la "Ambliopia tóxica", a propósito de un paciente tratado en este centro por exposición tóxica en su medio laboral, y es el resultado de ello la pérdida total de su visión y la consiguiente incapacidad laboral absoluta y permanente. Se recomienda hacer divulgación entre los obreros que trabajen con sustancias tóxicas y que les pueda traer como consecuencia esta grave afección (AU)


Subject(s)
Adult , Humans , Male , Methanol/poisoning , Blindness/chemically induced , Occupational Diseases
15.
Rev. cuba. med ; 25(9): 850-6, sept. 1986. ilus
Article in Spanish | LILACS | ID: lil-44376

ABSTRACT

Se hace una revisión bibliográfica por los autores de la literatura mundial acerca de la "Ambliopia tóxica", a propósito de un paciente tratado en este centro por exposición tóxica en su medio laboral, y es el resultado de ello la pérdida total de su visión y la consiguiente incapacidad laboral absoluta y permanente. Se recomienda hacer divulgación entre los obreros que trabajen con sustancias tóxicas y que les pueda traer como consecuencia esta grave afección


Subject(s)
Adult , Humans , Male , Blindness/chemically induced , Methanol/poisoning , Occupational Diseases
16.
Rev. bras. anestesiol ; 36(2): 95-9, mar.-abr. 1986. tab, ilus
Article in Portuguese | LILACS | ID: lil-38416

ABSTRACT

O problema da fibroplasia retrocristaliniana está sendo indevidamente subestimado entre nós. Acreditam-se que os dados expostos comprovam esta assertiva e indica-se o recrudescimento da fibroplasia retrocristaliniana. Um exame minucioso da retina periférica é um meio eficaz para o reconhecimento das alteraçöes iniciais da fibroplasia retrocristaliniana, prevenindo problemas médico-legais. Os anestesiologistas têm papel importante na contra-indicaçäo de cirurgias eletivas em crianças com menos de 45 semanas de idade gestacional ou com peso inferior a 4,6 kg. A ventilaçäo de recém-nascidos deve ser feita com ar e rigoroso controle PaO2, que näo deve ultrapassar 10-12kPa (80-90 mmHg), deve ser feito por meio dos monitores transcutâneos de PaO2


Subject(s)
Infant, Newborn , Humans , Male , Female , Blindness/chemically induced , Oxygen/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL